Drug Shortage Report for SANDOSTATIN
Report ID | 175439 |
Drug Identification Number | 00839191 |
Brand name | SANDOSTATIN |
Common or Proper name | SANDOSTATIN 50UG 1X5 AMPS |
Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | OCTREOTIDE |
Strength(s) | 50MCG |
Dosage form(s) | SOLUTION |
Route of administration | SUBCUTANEOUS INTRAVENOUS SUBCUTANEOUS INTRAVENOUS |
Packaging size | 1X5 AMPS |
ATC code | H01CB |
ATC description | HYPOTHALAMIC HORMONES |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2022-09-16 |
Estimated end date | 2023-02-13 |
Actual end date | 2023-02-10 |
Shortage status | Resolved |
Updated date | 2023-02-11 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v11 | 2023-02-11 | English | Compare |
v10 | 2023-02-10 | French | Compare |
v9 | 2023-02-10 | English | Compare |
v8 | 2023-02-10 | French | Compare |
v7 | 2023-02-10 | English | Compare |
v6 | 2023-02-06 | French | Compare |
v5 | 2023-02-06 | English | Compare |
v4 | 2023-01-25 | French | Compare |
v3 | 2023-01-25 | English | Compare |
v2 | 2022-11-22 | French | Compare |
v1 | 2022-11-22 | English | Compare |
Showing 1 to 11 of 11